Sanaz Vakili

Sanaz Vakili is a clinical trial assistant at Optimal Clinical Trials since December 2023, having previously served as a quality assurance officer at GMP Pharmaceuticals Ltd. from June to December 2023 and a research scientist at Auxilio Pharmaceuticals Limited from May to October 2022, where research focused on the effects of CBD on human coronary artery endothelial cells. Sanaz's doctoral research at The University of Auckland from April 2018 to April 2022 examined a genetic variant within the CREBRF gene related to increased BMI, height, and reduced Type 2 diabetes risk. Additional roles include vice president of FMHS-PGSA, international committee member, and research assistant during a PhD tenure, along with university lecturer experience at Shiraz University of Medical Sciences from January 2014 to January 2018. Sanaz holds a PhD in Molecular Medicine and Pathology from The University of Auckland, an MS in Clinical Biochemistry from Tehran University of Medical Sciences, and a BS in Chemistry from Shiraz University.